Cargando…

Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer

We compared cell-free DNA (cfDNA) results at MBC diagnosis in patients who developed brain metastases (BM) vs those without (non-BM) to understand genomic predictors of BM. Patients with cfDNA testing at MBC diagnosis (Guardant360®, 73 gene next generation sequencing) were identified. Clinical and g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vidula, Neelima, Niemierko, Andrzej, Hesler, Katherine, Ryan, Lianne, Moy, Beverly, Isakoff, Steven, Ellisen, Leif, Juric, Dejan, Bardia, Aditya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115848/ https://www.ncbi.nlm.nih.gov/pubmed/37076495 http://dx.doi.org/10.1038/s41523-023-00528-z

Ejemplares similares

Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer
por: Vidula, Neelima, et al.
Publicado: (2021)

Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer
por: Medford, Arielle J., et al.
Publicado: (2019)

Novel antibody–drug conjugates for triple negative breast cancer
por: Nagayama, Aiko, et al.
Publicado: (2020)

Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer
por: Vidula, Neelima, et al.
Publicado: (2022)

Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology
por: Vidula, Neelima, et al.
Publicado: (2017)

Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer
por: Denault, Elyssa, et al.
Publicado: (2022)

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
por: Spring, Laura M., et al.
Publicado: (2021)

TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis
por: Medford, Arielle J., et al.
Publicado: (2023)

Mechanisms of Resistance to Antibody–Drug Conjugates
por: Abelman, Rachel Occhiogrosso, et al.
Publicado: (2023)

Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series
por: Brett, Jamie O, et al.
Publicado: (2022)

Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53
por: Scarpetti, Lauren, et al.
Publicado: (2023)

Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic
por: Spring, Laura M., et al.
Publicado: (2020)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer
por: Coates, James T., et al.
Publicado: (2021)

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations
por: Spring, Laura M., et al.
Publicado: (2017)

Feasibility of introducing a smartphone navigation application into the care of breast cancer patients (The FIONA Study)
por: Isakoff, Steven J., et al.
Publicado: (2023)

Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer
por: McCarthy, Anne Marie, et al.
Publicado: (2020)

Cognitive Computing to Guide Molecular‐Based Therapy Selection: Steps Forward amid Abundant Need
por: Ellisen, Leif W.
Publicado: (2018)

A wound-healing program is hijacked to promote cancer metastasis
por: Ellisen, Leif W.
Publicado: (2017)

Post-operative radiation therapy to the surgical cavity with standard fractionation in patients with brain metastases
por: Byrne, James D., et al.
Publicado: (2020)

A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity
por: Ory, Benjamin, et al.
Publicado: (2011)

Notch signaling mediates p63-induced quiescence: A new facet of p63/Notch crosstalk
por: Forster, Nicole, et al.
Publicado: (2011)

Revisiting Androgen Receptor Signaling in Breast Cancer
por: Dai, Charles, et al.
Publicado: (2023)

The impact of different stereotactic radiation therapy regimens for brain metastases on local control and toxicity
por: Jimenez, Rachel B., et al.
Publicado: (2017)

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
por: Brett, Jamie O., et al.
Publicado: (2021)

Androgen receptor gene expression in primary breast cancer
por: Vidula, Neelima, et al.
Publicado: (2019)

A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry
por: Smith, Barbara L., et al.
Publicado: (2020)

Volatile Semiochemicals Increase Trap Catch of Green Lacewings (Neuroptera: Chrysopidae) and Flower Flies (Diptera: Syrphidae) in Corn and Soybean Plots
por: Hesler, Louis S.
Publicado: (2016)

Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma
por: Tawbi, Hussein, et al.
Publicado: (2022)

Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital
por: Bardia, Aditya, et al.
Publicado: (2016)

Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
por: Spring, Laura M., et al.
Publicado: (2022)

Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
por: Spring, Laura M., et al.
Publicado: (2022)

Utility of plasma cell‐free DNA in metastatic castration‐resistant prostate cancer
por: Hamano, Itsuto, et al.
Publicado: (2020)

Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer
por: Pereira, Bernard, et al.
Publicado: (2021)

North American species of Gymnopilus /
por: Hesler, Lexemuel Ray
Publicado: (1969)

Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role
por: Lloyd, Maxwell R., et al.
Publicado: (2022)

Pharmacodynamic study of Disulfiram in Men with Non-metastatic Recurrent Prostate Cancer
por: Schweizer, Michael T., et al.
Publicado: (2013)

"Summary Page": a novel tool that reduces omitted data in research databases
por: Goldberg, Saveli I, et al.
Publicado: (2010)

Prognostic Factors in Patients with Metastatic Breast Cancer with Bone‐Only Metastases
por: Parkes, Amanda, et al.
Publicado: (2018)

Announcing a New Journal Section: Community Outreach
por: Evans, Michele, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j4lj93n3ubbsb15ra8t9i8dqg1